Search hospitals

>

Minnesota

>

Duluth

Miller-Dwan Hospital

Claim this profile

Duluth, Minnesota 55805

Global Leader in Breast Cancer

Global Leader in Lung Cancer

Conducts research for Breast cancer

Conducts research for Prostate Cancer

Conducts research for Brain Tumor

307 reported clinical trials

2 medical researchers

Photo of Miller-Dwan Hospital in DuluthPhoto of Miller-Dwan Hospital in DuluthPhoto of Miller-Dwan Hospital in Duluth

Summary

Miller-Dwan Hospital is a medical facility located in Duluth, Minnesota. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Prostate Cancer, Brain Tumor and other specialties. Miller-Dwan Hospital is involved with conducting 307 clinical trials across 402 conditions. There are 2 research doctors associated with this hospital, such as Bret E. Friday and Bret EB Friday.

Area of expertise

1

Breast Cancer

Global Leader

Miller-Dwan Hospital has run 65 trials for Breast Cancer. Some of their research focus areas include:

ER positive
HER2 negative
HER2 positive
2

Lung Cancer

Global Leader

Miller-Dwan Hospital has run 54 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage II
Stage III

Top PIs

Clinical Trials running at Miller-Dwan Hospital

Bladder Cancer

Lung Cancer

Breast Cancer

Prostate Cancer

Ovarian Cancer

Kidney Cancer

Bladder Carcinoma

Laryngeal Cancer

Oropharyngeal Carcinoma

Pancreatic Cancer

Image of trial facility.

Immunotherapy + Targeted Therapy

for Genitourinary Cancers

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.

Recruiting

1 award

Phase 2

21 criteria

Image of trial facility.

Pembrolizumab + Radiation

for Bladder Cancer

This phase II trial compares the use of pembrolizumab and radiation therapy to chemotherapy with cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C and radiation therapy for the treatment of non-muscle invasive bladder cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving pembrolizumab with radiation may kill more tumor cells than chemotherapy with radiation therapy in patients with non-muscle invasive bladder cancer.

Recruiting

1 award

Phase 2

9 criteria

Image of trial facility.

Gemcitabine + Cisplatin

for Bladder Cancer

This phase II trial studies how well gemcitabine hydrochloride and cisplatin work in treating participants with invasive bladder urothelial cancer. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Recruiting

1 award

Phase 2

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Miller-Dwan Hospital?